Ontology highlight
ABSTRACT:
SUBMITTER: Gooding S
PROVIDER: S-EPMC4569348 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
Gooding Sarah S Lau I-Jun IJ Sheikh Mimi M Roberts Pamela P Wong Julia J Dickens Emmy E Bullement Ash A Elvidge Jamie J Lee Dawn D Ramasamy Karthik K
PloS one 20150914 9
Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was £23,472 [range: £1,411-£90,262], split betwe ...[more]